Name: Magnesium oxide

---

Type: small molecule

---

Groups: approved

---

Indication: Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.

---

Accession Number: DB01377 ( DB01377)

---

Description: Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses. [PubChem]

---

Structure:

---

Prescription Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
B6 Plus Tab	tablet	Array	oral	31-12-1979	01-08-2002	Canada
Calcium Magnesium Tab	tablet	Array	oral	31-12-1979	09-09-1996	Canada
Citracleen	powder for solution	Array	oral	01-01-1970		Canada
Cyclo/mag	kit	Array	Array	09-03-2010		US
Cyclo/mag 10mg/200mg	kit	Array	Array	17-02-2010		US
Kidmag Vitamins W Magnesium Tab	tablet	Array	oral	31-12-1989	02-10-1996	Canada
Magnesium Cap	capsule	Array	oral	31-12-1983	12-06-2002	Canada
Migralex Dr. Mauskop	tablet, coated	Array	oral	15-11-2009		US
One To One Cal-mag Tab 500mg	tablet	Array	oral	31-12-1985	17-09-1997	Canada
Oral Purgative	powder for solution	Array	oral	16-11-2011		Canada
Pico-salax	powder for solution	Array	oral	25-11-2004		Canada
Picodan	powder for solution	Array	oral	17-10-2007	31-12-2012	Canada
Picoflo	powder for solution	Array	oral	25-03-2011		Canada
Prenate Star	tablet, coated	Array	oral	05-06-2014		US
Purg-odan	powder for solution	Array	oral	16-02-2009		Canada
Strovite One Caplets	tablet	Array	oral	04-05-2001		US
Usana Active Calcium	tablet, chewable	Array	oral	28-03-2012		US
Virt-bal DHA Plus	kit	Array	Array	12-07-2012		US
Virt-PN	tablet, coated	Array	oral	12-07-2012		US
Virt-PN Plus	capsule, gelatin coated	Array	oral	01-03-2013		US

---

Generic Prescription Products: Not Available

---

Over the Counter Products:

Name	Dosage	Strength	Route	Marketing Start	Marketing End	Country
Magnesium Citrate Oral Solution	liquid	1.75 g	oral	31-12-1951	11-07-2003	Canada
Magnesium Oxide	tablet	400 mg/1	oral	08-09-2015		US
Magnesium Oxide	tablet	400 mg/1	oral	15-07-2004		US
Magnesium Oxide	tablet	400 mg/1	oral	01-01-2013		US
Magnesium Oxide	tablet	400 mg/1	oral	09-04-2014		US
Magnesium Oxide	tablet	400 mg/1	oral	30-09-2014		US
Magnesium Oxide	tablet	400 mg/1	oral	03-12-2003		US
Magnesium Oxide	tablet	253 mg/1	oral	06-10-2003		US
Magnesium Oxide 420 - Caplet	tablet	250 mg	oral	31-12-1995	18-07-2002	Canada
Magnesium Oxide Tab 420mg	tablet	420 mg	oral	31-12-1988	17-07-2008	Canada
Magnesium Tab 250mg	tablet	410 mg	oral	31-12-1987	05-07-2006	Canada

---

International Brands

• No Brands

---

Brand Names

• No Brands

---

Brand Mixtures

Brand Name	Ingredients
Magnesium Oxide	Magnesium oxide
Magnesium Oxide	Magnesium oxide
Strovite One Caplets	Vitamin A + Pantothenic acid + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Biotin + Cyanocobalamin + Selenium + Magnesium oxide + Zinc oxide + Cupric sulfate + Manganese + Chromium + Lipoic Acid + Lutein
Magnesium Oxide	Magnesium oxide
Migralex Dr. Mauskop	Acetylsalicylic acid + Magnesium oxide
Usana Active Calcium	Calcium carbonate + Magnesium oxide + Cholecalciferol + Calcium citrate + Magnesium citrate
Magnesium Oxide	Magnesium oxide
Magnesium Oxide	Magnesium oxide
Cyclo/mag	Cyclobenzaprine + Magnesium oxide
Cyclo/mag 10mg/200mg	Cyclobenzaprine + Magnesium oxide
Magnesium Oxide	Magnesium oxide
Prenate Star	Beta carotene + Vitamin C + Cholecalciferol + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Cyanocobalamin + Biotin + Pantothenic acid + Formic Acid + Ferrous asparto glycinate + Potassium Iodide + Magnesium oxide + Zinc oxide + Cupric oxide
Magnesium Oxide	Magnesium oxide
Virt-bal DHA Plus	Folic Acid + Pyridoxine + Calcium carbonate + Sodium ascorbate + Cholecalciferol + Acetic acid + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Ferrous bisglycinate + Iodine + Zinc oxide + Cupric oxide + Beta carotene + Magnesium oxide + Doconexent + Icosapent
Virt-PN	Levomefolic acid + Pyridoxine + Beta carotene + Calcium carbonate + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Iron + Potassium Iodide + Zinc oxide + Biotin + Pantothenic acid + Magnesium oxide + Cupric oxide
Virt-PN Plus	Folic Acid + Vitamin C + Cholecalciferol + Vitamin E + Pyridoxine + Cyanocobalamin + Biotin + Calcium carbonate + Iron + Potassium Iodide + Magnesium oxide + Doconexent + Icosapent
Pico-salax	Citric Acid + Sodium picosulfate + Magnesium oxide
Purg-odan	Citric Acid + Sodium picosulfate + Magnesium oxide
Picoflo	Citric Acid + Sodium picosulfate + Magnesium oxide
Oral Purgative	Citric Acid + Sodium picosulfate + Magnesium oxide
Magnesium Citrate Oral Solution	Magnesium oxide
Magnesium Oxide 420 - Caplet	Magnesium oxide
B6 Plus Tab	Thiamine + Riboflavin + Pyridoxine + Niacin + Potassium Citrate + Magnesium oxide
Calcium Magnesium Tab	Calcium carbonate + Magnesium oxide
Magnesium Cap	Magnesium oxide + Magnesium Sulfate
One To One Cal-mag Tab 500mg	Calcium + Magnesium oxide
Picodan	Citric Acid + Sodium picosulfate + Magnesium oxide
Magnesium Tab 250mg	Magnesium oxide
Magnesium Oxide Tab 420mg	Magnesium oxide
Kidmag Vitamins W Magnesium Tab	Pyridoxine + Vitamin C + Vitamin A + Magnesium oxide
Citracleen	Citric Acid + Sodium picosulfate + Magnesium oxide

Brand Name	Ingredients
Magnesium Oxide	Magnesium oxide
Magnesium Oxide	Magnesium oxide
Strovite One Caplets	Vitamin A + Pantothenic acid + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Biotin + Cyanocobalamin + Selenium + Magnesium oxide + Zinc oxide + Cupric sulfate + Manganese + Chromium + Lipoic Acid + Lutein
Magnesium Oxide	Magnesium oxide
Migralex Dr. Mauskop	Acetylsalicylic acid + Magnesium oxide
Usana Active Calcium	Calcium carbonate + Magnesium oxide + Cholecalciferol + Calcium citrate + Magnesium citrate
Magnesium Oxide	Magnesium oxide
Magnesium Oxide	Magnesium oxide
Cyclo/mag	Cyclobenzaprine + Magnesium oxide
Cyclo/mag 10mg/200mg	Cyclobenzaprine + Magnesium oxide
Magnesium Oxide	Magnesium oxide
Prenate Star	Beta carotene + Vitamin C + Cholecalciferol + Thiamine + Riboflavin + Nicotinamide + Pyridoxine + Folic Acid + Cyanocobalamin + Biotin + Pantothenic acid + Formic Acid + Ferrous asparto glycinate + Potassium Iodide + Magnesium oxide + Zinc oxide + Cupric oxide
Magnesium Oxide	Magnesium oxide
Virt-bal DHA Plus	Folic Acid + Pyridoxine + Calcium carbonate + Sodium ascorbate + Cholecalciferol + Acetic acid + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Ferrous bisglycinate + Iodine + Zinc oxide + Cupric oxide + Beta carotene + Magnesium oxide + Doconexent + Icosapent
Virt-PN	Levomefolic acid + Pyridoxine + Beta carotene + Calcium carbonate + Vitamin C + Cholecalciferol + Vitamin E + Thiamine + Riboflavin + Nicotinamide + Cyanocobalamin + Iron + Potassium Iodide + Zinc oxide + Biotin + Pantothenic acid + Magnesium oxide + Cupric oxide
Virt-PN Plus	Folic Acid + Vitamin C + Cholecalciferol + Vitamin E + Pyridoxine + Cyanocobalamin + Biotin + Calcium carbonate + Iron + Potassium Iodide + Magnesium oxide + Doconexent + Icosapent
Pico-salax	Citric Acid + Sodium picosulfate + Magnesium oxide
Purg-odan	Citric Acid + Sodium picosulfate + Magnesium oxide
Picoflo	Citric Acid + Sodium picosulfate + Magnesium oxide
Oral Purgative	Citric Acid + Sodium picosulfate + Magnesium oxide
Magnesium Citrate Oral Solution	Magnesium oxide
Magnesium Oxide 420 - Caplet	Magnesium oxide
B6 Plus Tab	Thiamine + Riboflavin + Pyridoxine + Niacin + Potassium Citrate + Magnesium oxide
Calcium Magnesium Tab	Calcium carbonate + Magnesium oxide
Magnesium Cap	Magnesium oxide + Magnesium Sulfate
One To One Cal-mag Tab 500mg	Calcium + Magnesium oxide
Picodan	Citric Acid + Sodium picosulfate + Magnesium oxide
Magnesium Tab 250mg	Magnesium oxide
Magnesium Oxide Tab 420mg	Magnesium oxide
Kidmag Vitamins W Magnesium Tab	Pyridoxine + Vitamin C + Vitamin A + Magnesium oxide
Citracleen	Citric Acid + Sodium picosulfate + Magnesium oxide

---

Categories

• Antacids

Indication: Magnesium hydroxide is used as a laxative to relieve occasional constipation (irregularity) and as an antacid to relieve indigestion, sour stomach, and heartburn.

---

Pharmacodynamics: Not Available

---

Mechanism of action: The term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.

---

Absorption: Not Available

---

Volume of distribution: Not Available

---

Protein binding: Not Available

---

Metabolism: Not Available

---

Route of elimination: Not Available

---

Half life: Not Available

---

Clearance: Not Available

---

Toxicity: Not Available

---

Affected organisms

• Not Available

---

SNP Mediated Adverse Drug Reactions

• Not Available

Manufacturers:

• Not Available

---

Packagers:

• Bayer Healthcare
• Blaine Pharmaceuticals
• Gallipot
• Major Pharmaceuticals
• Manne Co.
• Mckesson Corp.
• Particle Dynamics Co.
• Qualitest
• Rising Pharmaceuticals
• Rugby Laboratories
• Walgreen Co.

---

Dosage forms

Form	Route	Strength
Kit
Capsule	oral
Liquid	oral	1.75 g
Tablet	oral	253 mg/1
Tablet	oral	400 mg/1
Tablet	oral	250 mg
Tablet	oral	420 mg
Tablet	oral	410 mg
Tablet, coated	oral
Powder for solution	oral
Tablet	oral
Tablet, chewable	oral
Capsule, gelatin coated	oral

Form	Route	Strength
Kit
Capsule	oral
Liquid	oral	1.75 g
Tablet	oral	253 mg/1
Tablet	oral	400 mg/1
Tablet	oral	250 mg
Tablet	oral	420 mg
Tablet	oral	410 mg
Tablet, coated	oral
Powder for solution	oral
Tablet	oral
Tablet, chewable	oral
Capsule, gelatin coated	oral

---

Prices

Unit description	Cost	Unit
Magnesium oxide 250 mg tablet	$0.03	tablet
Magnesium oxide 500 mg tablet	$0.04	tablet
Maox 420 mg tablet	$0.04	tablet
Magnesium oxide powder heavy	$0.05	g
Mag-oxide 400 mg tablet	$0.09	tablet
Magnesium oxide 420 mg tablet	$0.11	tablet
Magox 400 tablet	$0.11	tablet
Magnesium oxide 400 mg tablet	$0.13	tablet
Phillips 500 mg caplet	$0.18	caplet

Unit description	Cost	Unit
Magnesium oxide 250 mg tablet	$0.03	tablet
Magnesium oxide 500 mg tablet	$0.04	tablet
Maox 420 mg tablet	$0.04	tablet
Magnesium oxide powder heavy	$0.05	g
Mag-oxide 400 mg tablet	$0.09	tablet
Magnesium oxide 420 mg tablet	$0.11	tablet
Magox 400 tablet	$0.11	tablet
Magnesium oxide 400 mg tablet	$0.13	tablet
Phillips 500 mg caplet	$0.18	caplet

---

Patents

Country	Patent Number	Approved	Expires (estimated)

Drug Interactions

Drug	Interaction
Alendronate	The serum concentration of Alendronate can be decreased when it is combined with Magnesium oxide.
Alfacalcidol	The serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol.
Allopurinol	Magnesium oxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide.
Amphetamine	Magnesium oxide may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Amrinone	The risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium oxide.
Atazanavir	Magnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Atorvastatin	The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.
Benzphetamine	Magnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Bepridil	The risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.
Biotin	Magnesium oxide can cause a decrease in the absorption of Biotin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bisacodyl	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide.
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide.
Budesonide	The bioavailability of Budesonide can be decreased when combined with Magnesium oxide.
Calcitriol	The serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol.
Captopril	The serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.
Cefditoren	The serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide.
Cefpodoxime	The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide.
Cefuroxime	The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide.
Chloroquine	The serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide.
Chlorpromazine	Magnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciprofloxacin	Magnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clodronate	The serum concentration of Clodronate can be decreased when it is combined with Magnesium oxide.
Cortisone acetate	The bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide.
Cysteamine	The therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium oxide.
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.
Dabrafenib	The serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide.
Dasatinib	Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deferiprone	The serum concentration of Deferiprone can be decreased when it is combined with Magnesium oxide.
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide.
Demeclocycline	Magnesium oxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexamethasone	The bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.
Dexmethylphenidate	Magnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dextroamphetamine	Magnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Dolutegravir	The serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide.
Doxycycline	Magnesium oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Eltrombopag	The serum concentration of Eltrombopag can be decreased when it is combined with Magnesium oxide.
Elvitegravir	The serum concentration of Elvitegravir can be decreased when it is combined with Magnesium oxide.
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide.
Felodipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.
Fexofenadine	The serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide.
Fludrocortisone	The bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.
Flunarizine	The risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide.
Fluphenazine	Magnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluvastatin	The serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide.
Fosinopril	The serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.
Gabapentin	Magnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Magnesium oxide.
Gemifloxacin	Magnesium oxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hexamethylenetetramine	The therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium oxide.
Hydrocortisone	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.
Hyoscyamine	The serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide.
Ibandronate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.
Isoniazid	Magnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide.
Itraconazole	The serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide.
Ketoconazole	The serum concentration of Ketoconazole can be decreased when it is combined with Magnesium oxide.
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide.
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Magnesium oxide.
Lercanidipine	The risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide.
Levofloxacin	Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levothyroxine	The serum concentration of Levothyroxine can be decreased when it is combined with Magnesium oxide.
Lipoic Acid	Magnesium oxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lisdexamfetamine	Magnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Lovastatin	The serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide.
Magnesium Sulfate	The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide.
Mesalazine	The therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide.
Methamphetamine	Magnesium oxide may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Methotrimeprazine	Magnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate	Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methylprednisolone	The bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.
Minocycline	Magnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Misoprostol	The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol.
Moxifloxacin	Magnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolate mofetil	Magnesium oxide can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acid	The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.
Nilotinib	The serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide.
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide.
Nitrendipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.
Norfloxacin	Magnesium oxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ofloxacin	Magnesium oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline	Magnesium oxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazopanib	The serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.
Penicillamine	The serum concentration of Penicillamine can be decreased when it is combined with Magnesium oxide.
Perhexiline	The risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium oxide.
Perphenazine	Magnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Phendimetrazine	Magnesium oxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
Phentermine	Magnesium oxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
Pipotiazine	Magnesium oxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide.
Polystyrene sulfonate	The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Polystyrene sulfonate.
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.
Prednisolone	The bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.
Prednisone	The bioavailability of Prednisone can be decreased when combined with Magnesium oxide.
Prenylamine	The risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide.
Prochlorperazine	Magnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promazine	Magnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Quinidine	Magnesium oxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Quinine	The serum concentration of Quinine can be decreased when it is combined with Magnesium oxide.
Raltegravir	The serum concentration of Raltegravir can be decreased when it is combined with Magnesium oxide.
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Magnesium oxide.
Riociguat	The serum concentration of Riociguat can be decreased when it is combined with Magnesium oxide.
Risedronate	The serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.
Rosuvastatin	The serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide.
Simvastatin	The serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide.
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Magnesium oxide.
Sotalol	The serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium oxide.
Tetracycline	Magnesium oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioridazine	Magnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tiludronate	The serum concentration of Tiludronate can be decreased when it is combined with Magnesium oxide.
Triethylenetetramine	The serum concentration of Magnesium oxide can be decreased when it is combined with Triethylenetetramine.
Trifluoperazine	Magnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.

Drug	Interaction
Alendronate	The serum concentration of Alendronate can be decreased when it is combined with Magnesium oxide.
Alfacalcidol	The serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol.
Allopurinol	Magnesium oxide can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Magnesium oxide.
Amphetamine	Magnesium oxide may decrease the excretion rate of Amphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Amrinone	The risk or severity of adverse effects can be increased when Amrinone is combined with Magnesium oxide.
Atazanavir	Magnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Atorvastatin	The serum concentration of Atorvastatin can be decreased when it is combined with Magnesium oxide.
Benzphetamine	Magnesium oxide may decrease the excretion rate of Benzphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Bepridil	The risk or severity of adverse effects can be increased when Bepridil is combined with Magnesium oxide.
Biotin	Magnesium oxide can cause a decrease in the absorption of Biotin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Bisacodyl	The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide.
Bosutinib	The serum concentration of Bosutinib can be decreased when it is combined with Magnesium oxide.
Budesonide	The bioavailability of Budesonide can be decreased when combined with Magnesium oxide.
Calcitriol	The serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol.
Captopril	The serum concentration of Captopril can be decreased when it is combined with Magnesium oxide.
Cefditoren	The serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide.
Cefpodoxime	The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide.
Cefuroxime	The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide.
Chloroquine	The serum concentration of Chloroquine can be decreased when it is combined with Magnesium oxide.
Chlorpromazine	Magnesium oxide can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ciprofloxacin	Magnesium oxide can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clodronate	The serum concentration of Clodronate can be decreased when it is combined with Magnesium oxide.
Cortisone acetate	The bioavailability of Cortisone acetate can be decreased when combined with Magnesium oxide.
Cysteamine	The therapeutic efficacy of Cysteamine can be decreased when used in combination with Magnesium oxide.
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Magnesium oxide.
Dabrafenib	The serum concentration of Dabrafenib can be decreased when it is combined with Magnesium oxide.
Dasatinib	Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.
Deferiprone	The serum concentration of Deferiprone can be decreased when it is combined with Magnesium oxide.
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Magnesium oxide.
Demeclocycline	Magnesium oxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dexamethasone	The bioavailability of Dexamethasone can be decreased when combined with Magnesium oxide.
Dexmethylphenidate	Magnesium oxide can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Dextroamphetamine	Magnesium oxide may decrease the excretion rate of Dextroamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Dolutegravir	The serum concentration of Dolutegravir can be decreased when it is combined with Magnesium oxide.
Doxycycline	Magnesium oxide can cause a decrease in the absorption of Doxycycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Eltrombopag	The serum concentration of Eltrombopag can be decreased when it is combined with Magnesium oxide.
Elvitegravir	The serum concentration of Elvitegravir can be decreased when it is combined with Magnesium oxide.
Erlotinib	The serum concentration of Erlotinib can be decreased when it is combined with Magnesium oxide.
Felodipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.
Fexofenadine	The serum concentration of Fexofenadine can be decreased when it is combined with Magnesium oxide.
Fludrocortisone	The bioavailability of Fludrocortisone can be decreased when combined with Magnesium oxide.
Flunarizine	The risk or severity of adverse effects can be increased when Flunarizine is combined with Magnesium oxide.
Fluphenazine	Magnesium oxide can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Fluvastatin	The serum concentration of Fluvastatin can be decreased when it is combined with Magnesium oxide.
Fosinopril	The serum concentration of Fosinopril can be decreased when it is combined with Magnesium oxide.
Gabapentin	Magnesium oxide may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.
Gefitinib	The serum concentration of Gefitinib can be decreased when it is combined with Magnesium oxide.
Gemifloxacin	Magnesium oxide can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Hexamethylenetetramine	The therapeutic efficacy of Hexamethylenetetramine can be decreased when used in combination with Magnesium oxide.
Hydrocortisone	The bioavailability of Hydrocortisone can be decreased when combined with Magnesium oxide.
Hyoscyamine	The serum concentration of Hyoscyamine can be decreased when it is combined with Magnesium oxide.
Ibandronate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.
Isoniazid	Magnesium oxide can cause a decrease in the absorption of Isoniazid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Magnesium oxide.
Itraconazole	The serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide.
Ketoconazole	The serum concentration of Ketoconazole can be decreased when it is combined with Magnesium oxide.
Lamotrigine	The risk or severity of adverse effects can be increased when Lamotrigine is combined with Magnesium oxide.
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Magnesium oxide.
Lercanidipine	The risk or severity of adverse effects can be increased when Lercanidipine is combined with Magnesium oxide.
Levofloxacin	Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Levothyroxine	The serum concentration of Levothyroxine can be decreased when it is combined with Magnesium oxide.
Lipoic Acid	Magnesium oxide can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
Lisdexamfetamine	Magnesium oxide may decrease the excretion rate of Lisdexamfetamine which could result in a lower serum level and potentially a reduction in efficacy.
Lovastatin	The serum concentration of Lovastatin can be decreased when it is combined with Magnesium oxide.
Magnesium Sulfate	The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Magnesium oxide.
Mesalazine	The therapeutic efficacy of Mesalazine can be decreased when used in combination with Magnesium oxide.
Methamphetamine	Magnesium oxide may decrease the excretion rate of Methamphetamine which could result in a lower serum level and potentially a reduction in efficacy.
Methotrimeprazine	Magnesium oxide can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Methylphenidate	Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.
Methylprednisolone	The bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.
Minocycline	Magnesium oxide can cause a decrease in the absorption of Minocycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Misoprostol	The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol.
Moxifloxacin	Magnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolate mofetil	Magnesium oxide can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Mycophenolic acid	The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide.
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Magnesium oxide.
Nilotinib	The serum concentration of Nilotinib can be decreased when it is combined with Magnesium oxide.
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Magnesium oxide.
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Magnesium oxide.
Nitrendipine	The risk or severity of adverse effects can be increased when Nitrendipine is combined with Magnesium oxide.
Norfloxacin	Magnesium oxide can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ofloxacin	Magnesium oxide can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Oxytetracycline	Magnesium oxide can cause a decrease in the absorption of Oxytetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pazopanib	The serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.
Penicillamine	The serum concentration of Penicillamine can be decreased when it is combined with Magnesium oxide.
Perhexiline	The risk or severity of adverse effects can be increased when Perhexiline is combined with Magnesium oxide.
Perphenazine	Magnesium oxide can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Phendimetrazine	Magnesium oxide may decrease the excretion rate of Phendimetrazine which could result in a lower serum level and potentially a reduction in efficacy.
Phentermine	Magnesium oxide may decrease the excretion rate of Phentermine which could result in a lower serum level and potentially a reduction in efficacy.
Pipotiazine	Magnesium oxide can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Magnesium oxide.
Polystyrene sulfonate	The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Polystyrene sulfonate.
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.
Prednisolone	The bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.
Prednisone	The bioavailability of Prednisone can be decreased when combined with Magnesium oxide.
Prenylamine	The risk or severity of adverse effects can be increased when Prenylamine is combined with Magnesium oxide.
Prochlorperazine	Magnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Promazine	Magnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Quinidine	Magnesium oxide may decrease the excretion rate of Quinidine which could result in a lower serum level and potentially a reduction in efficacy.
Quinine	The serum concentration of Quinine can be decreased when it is combined with Magnesium oxide.
Raltegravir	The serum concentration of Raltegravir can be decreased when it is combined with Magnesium oxide.
Rilpivirine	The serum concentration of Rilpivirine can be decreased when it is combined with Magnesium oxide.
Riociguat	The serum concentration of Riociguat can be decreased when it is combined with Magnesium oxide.
Risedronate	The serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.
Rosuvastatin	The serum concentration of Rosuvastatin can be decreased when it is combined with Magnesium oxide.
Simvastatin	The serum concentration of Simvastatin can be decreased when it is combined with Magnesium oxide.
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Magnesium oxide.
Sotalol	The serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium oxide.
Tetracycline	Magnesium oxide can cause a decrease in the absorption of Tetracycline resulting in a reduced serum concentration and potentially a decrease in efficacy.
Thioridazine	Magnesium oxide can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tiludronate	The serum concentration of Tiludronate can be decreased when it is combined with Magnesium oxide.
Triethylenetetramine	The serum concentration of Magnesium oxide can be decreased when it is combined with Triethylenetetramine.
Trifluoperazine	Magnesium oxide can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Magnesium oxide.

---

Food Interactions:

• Not Available

Kingdom: Inorganic compounds

---

Super Class: Not Available

---

Class: Not Available

---

Sub Class: Not Available

---

Direct Parent: Not Available

---

Alternative Parents:

---

substituent:

• Acyclic compound
• Inorganic oxide
• Miscellaneous mixed metal/non-metal

Synthesis Reference: Jajnya D. Panda, Santosh K. Mahapatra, "Process for the production of magnesium oxide from brine or bittern." U.S. Patent US4370422, issued June, 1921.

---

General Reference: # Kh R, Khullar M, Kashyap M, Pandhi P, Uppal R: Effect of oral magnesium supplementation on blood pressure, platelet aggregation and calcium handling in deoxycorticosterone acetate induced hypertension in rats. J Hypertens. 2000 Jul;18(7):919-26. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10930190 # Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S: Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999 Jul 15;84(2):152-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10426331

---

External Links:

Resource	Link
Drugs.com	http://www.drugs.com/cdi/magnesium-oxide.html

Resource	Link
Drugs.com	http://www.drugs.com/cdi/magnesium-oxide.html

---

ATC Codes:

• Array
• Array
• Array

---

AHFS Codes:

• 88:29.00*
• 92:02.00*

---

MSDS: Download